Recombinant Human EGF

Recombinant Human EGF

Size1:10μg price1:$30
Size2:50μg price2:$50
SKU: PCH2503 Category: Cytokines Tags: ,

Datasheet

Name

Recombinant Human EPO

Purity

Greater than 98% as determined by reducing SDS-PAGE

Endotoxin level

≤10 EU/mg

Construction

Recombinant Human EPO is produced by our Mammalian cell expression system and the target gene encoding Ala28-Arg193 is expressed.

Accession #

P01588

Host

Human Cells

Species

Human

Predicted Molecular Mass

18.3 kDa

Buffer

Lyophilized From 10 mM PB, pH 7.4

Form

Shipping

The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

Erythropoietin; Epoetin; EPO

 

Background

Erythropoietin (EPO) is a glycoprotein hormone that is principally known for its role in erythropoiesis, where it is responsible for stimulating proliferation and differentiation of erythroid progenitor cells. Erythropoietin is a member of the EPO/TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. The differentiation of CFU-E (Colony Forming Unit-Erythroid) cells into erythrocytes can only be accomplished in the presence of EPO. Physiological levels of EPO in adult mammals are maintained primarily by the kidneys, whereas levels in fetal or neonatal mammals are maintained by the liver. EPO also can exert various non-hematopoietic activities, including vascularization and proliferation of smooth muscle, neural protection during hypoxia, and stimulation of certain B cells. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy.

 

Note

For Research Use Only , Not for Diagnostic Use.